The global market for Urea Cycle Disorder Treatment was valued at US$1.3 Billion in 2025 and is projected to reach US$1.6 Billion by 2032, growing at a CAGR of 3.0% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Global Urea Cycle Disorder Treatment Market - Key Trends & Drivers Summarized
Why Is Effective Treatment for Urea Cycle Disorder Becoming Increasingly Crucial?
Urea cycle disorder (UCD) is a rare but serious group of inherited metabolic conditions that impair the body’s ability to eliminate ammonia, a toxic byproduct of protein metabolism. As awareness of genetic diseases grows and neonatal screening becomes more widespread, earlier diagnosis of UCD is driving greater attention toward timely and effective treatment options. Although the disorder is rare, its consequences can be life-threatening if left unmanaged, leading to irreversible brain damage, coma, or death, particularly in newborns and young children. This reality makes the development and availability of safe and efficient treatment protocols an urgent public health concern. UCD may present suddenly in infants or develop more gradually in adolescents and adults, which complicates diagnosis and often leads to delayed intervention. With improved genetic testing and metabolic screening methods, more cases are being identified early, resulting in increased demand for therapeutic interventions that can control ammonia levels and prevent acute hyperammonemic crises. The chronic nature of UCD also means that patients require lifelong management strategies, which often involve dietary control, ammonia scavenger medications, amino acid supplementation, and in severe cases, liver transplantation. The expanding diagnostic landscape, coupled with the growing number of identified cases through family screening and newborn panels, highlights why UCD treatment is becoming a more prominent focus within the rare disease and metabolic disorder space.How Are Treatment Innovations and Drug Developments Transforming UCD Management?
Treatment options for urea cycle disorder have advanced significantly in recent years, thanks to targeted research efforts, orphan drug designations, and deeper understanding of the disorder’s biochemical pathways. Traditional management strategies primarily involve protein-restricted diets to reduce ammonia production, supplemented with nitrogen-scavenging agents like sodium benzoate and sodium phenylbutyrate, which help remove excess nitrogen through alternative pathways. More recently, novel formulations such as glycerol phenylbutyrate have emerged, offering improved pharmacokinetics, better patient compliance, and reduced dosing frequency. These newer drugs are particularly valuable in pediatric care, where palatability and ease of administration are critical to long-term success. Additionally, therapeutic developments are focusing on restoring urea cycle function or compensating for the missing enzyme activity at a cellular level. Gene therapy and mRNA-based treatments are being actively explored, with preclinical and early-phase clinical trials showing promise for long-term correction of enzyme deficiencies. Enzyme replacement therapy is another avenue under investigation, aimed at reducing dependence on lifelong medication and strict dietary controls. Advances in metabolic monitoring tools are also improving treatment personalization, allowing clinicians to adjust therapeutic regimens based on real-time data from ammonia levels, amino acid concentrations, and patient metabolic responses. These innovations are transforming UCD from a condition that once had limited treatment options into a disease area where targeted and potentially curative therapies are on the horizon.What Role Do Healthcare Systems, Patient Advocacy, and Access to Diagnosis Play in Market Dynamics?
The management and treatment of urea cycle disorder are deeply influenced by the structure and responsiveness of healthcare systems, availability of diagnostic tools, and advocacy efforts from patient communities. In regions with well-developed neonatal screening programs, such as the United States and parts of Europe, early diagnosis and intervention significantly improve clinical outcomes, reduce the risk of cognitive impairment, and increase the lifespan and quality of life for patients. Access to specialized metabolic centers and trained healthcare providers also plays a crucial role in ensuring optimal treatment, as UCD requires multidisciplinary care involving dietitians, geneticists, neurologists, and metabolic specialists. In low- and middle-income countries, however, limited awareness and inadequate infrastructure often result in underdiagnosis or misdiagnosis, with many cases going untreated until symptoms become severe. Patient advocacy groups are stepping in to bridge these gaps by raising awareness, supporting education for healthcare professionals, and lobbying for inclusion of UCD in national newborn screening panels. These organizations also contribute by funding research, facilitating access to clinical trials, and helping patients navigate reimbursement and insurance processes for costly treatments. Access to genetic counseling and family testing further supports disease management by enabling early identification of at-risk individuals. Collectively, the role of healthcare infrastructure and community support is instrumental in shaping how UCD is diagnosed, treated, and managed across different regions and populations.What Are the Key Factors Driving Growth in the Urea Cycle Disorder Treatment Market?
The growth in the urea cycle disorder treatment market is driven by a blend of scientific progress, expanding diagnostic reach, and strategic healthcare initiatives aimed at addressing rare diseases. One of the most critical growth drivers is the rising incidence of diagnosed UCD cases, largely due to improvements in neonatal screening programs and increased genetic awareness. The availability of orphan drug incentives and regulatory fast-track designations is encouraging pharmaceutical companies to invest in research and development, resulting in a growing pipeline of innovative therapies aimed at better efficacy, fewer side effects, and improved patient adherence. Expanding access to metabolic testing and genetic counseling is helping identify both symptomatic and asymptomatic individuals, further increasing treatment uptake. Government and private sector investment in rare disease research is also contributing to the development of novel treatment modalities, including gene therapies and advanced biologics, which have the potential to offer long-term solutions or even curative outcomes. Additionally, the growing role of digital health technologies and remote monitoring tools is enabling more precise and continuous management of ammonia levels, improving clinical decision-making and reducing the need for hospitalizations. As patient awareness continues to grow and global healthcare systems prioritize rare disease coverage, demand for UCD treatments is expected to rise steadily. These interrelated factors are driving a sustained and promising expansion of the global urea cycle disorder treatment market, supported by both clinical necessity and innovation momentum.Report Scope
The report analyzes the Urea Cycle Disorder Treatment market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:- Segments: Therapy (Glycerol Phenylbutyrate Therapy, Sodium Phenylbutyrate Therapy, Amino Acid Supplements Therapy, Sodium Benzoate Therapy, Other Therapies); Administration Route (Oral Administration, Injectable Administration); End-Use (Hospitals End-Use, Specialized Clinics End-Use, Home Care Settings End-Use, Research Institutions End-Use)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Glycerol Phenylbutyrate Therapy segment, which is expected to reach US$604.6 Million by 2032 with a CAGR of a 3.6%. The Sodium Phenylbutyrate Therapy segment is also set to grow at 3.7% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $353.6 Million in 2025, and China, forecasted to grow at an impressive 5.4% CAGR to reach $314.8 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Urea Cycle Disorder Treatment Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Urea Cycle Disorder Treatment Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Urea Cycle Disorder Treatment Market expected to evolve by 2032?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2032?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Acer Therapeutics Inc., Aeglea BioTherapeutics Inc., Arcturus Therapeutics Holdings Inc., Abbott Laboratories Inc., Bausch Health Companies Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the companies featured in this Urea Cycle Disorder Treatment market report include:
- Acer Therapeutics Inc.
- Aeglea BioTherapeutics Inc.
- Arcturus Therapeutics Holdings Inc.
- Abbott Laboratories Inc.
- Bausch Health Companies Inc.
- BioMarin Pharmaceutical Inc.
- Censa Pharmaceuticals Inc.
- Danone S.A.
- Eurocept Pharmaceuticals (Lucane Pharma SA)
- Horizon Therapeutics plc
- Mead Johnson & Company, LLC
- Moderna, Inc.
- Orpharma Pty Ltd.
- Precision BioSciences
- Recordati Rare Diseases Inc.
- Relief Therapeutics Holding AG
- Selecta Biosciences Inc.
- Swedish Orphan Biovitrum AB (Sobi)
- Synlogic Inc.
- Ultragenyx Pharmaceutical Inc.
- Xenion Biotech, Inc.
What Sets This Report Apart From Others?
- Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
- Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
- Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
- Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
- Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
- Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
- How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
- Ureteral Stents - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
3. MARKET TRENDS & DRIVERS
- Rising Incidence of Urolithiasis and Urological Disorders Drives Demand for Ureteral Stents
- Growing Geriatric Population Prone to Chronic Kidney and Urinary Tract Conditions Expands Market Size
- Advancements in Stent Materials and Coatings Propel Development of Anti-Encrustation and Biofilm-Resistant Devices
- Increased Adoption of Minimally Invasive Urological Procedures Strengthens Business Case for Stent Placement
- Surge in Endourological Surgeries, Including Ureteroscopy and Percutaneous Nephrolithotomy, Spurs Stent Utilization
- Technological Innovations in Biodegradable and Drug-Eluting Stents Accelerate Product Diversification
- Rising Demand for Temporary and Long-Term Stent Solutions Enhances Growth Across Acute and Chronic Applications
- Integration of Imaging and Navigation Technologies Improves Placement Accuracy and Patient Outcomes
- Post-Surgical Stenting for Stone Removal and Obstruction Relief Sustains Use in Hospital and Outpatient Settings
- Growing Awareness and Diagnosis of Ureteral Obstruction and Strictures Fuel Early Intervention
- Patient-Centric Innovations in Comfort, Removal Ease, and Reduced Migration Enhance Compliance
- Increased Urology Specialization and Expansion of Surgical Centers Drive Procedural Volume
- Rising Focus on Reducing Hospital Stays and Readmissions Throws Spotlight on Advanced Ureteral Stent Technologies
- Table 1: World Ureteral Stents Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
- Table 2: World Recent Past, Current & Future Analysis for Ureteral Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- Table 3: World Historic Review for Ureteral Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 4: World 13-Year Perspective for Ureteral Stents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
- Table 5: World Recent Past, Current & Future Analysis for Metallic Ureteral Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- Table 6: World Historic Review for Metallic Ureteral Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 7: World 13-Year Perspective for Metallic Ureteral Stents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- Table 8: World Recent Past, Current & Future Analysis for Polymer Ureteral Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- Table 9: World Historic Review for Polymer Ureteral Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 10: World 13-Year Perspective for Polymer Ureteral Stents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- Table 11: World Recent Past, Current & Future Analysis for Kidney Stones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- Table 12: World Historic Review for Kidney Stones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 13: World 13-Year Perspective for Kidney Stones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- Table 14: World Recent Past, Current & Future Analysis for Kidney Transplantation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- Table 15: World Historic Review for Kidney Transplantation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 16: World 13-Year Perspective for Kidney Transplantation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- Table 17: World Recent Past, Current & Future Analysis for Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- Table 18: World Historic Review for Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 19: World 13-Year Perspective for Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- Table 20: World Recent Past, Current & Future Analysis for Urinary Incontinence by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- Table 21: World Historic Review for Urinary Incontinence by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 22: World 13-Year Perspective for Urinary Incontinence by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- Table 23: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- Table 24: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 25: World 13-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
UNITED STATES
- Ureteral Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
- Table 26: USA Recent Past, Current & Future Analysis for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 27: USA Historic Review for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 28: USA 13-Year Perspective for Ureteral Stents by Material - Percentage Breakdown of Value Sales for Metallic Ureteral Stents and Polymer Ureteral Stents for the Years 2020, 2026 & 2032
- Table 29: USA Recent Past, Current & Future Analysis for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 30: USA Historic Review for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 31: USA 13-Year Perspective for Ureteral Stents by Application - Percentage Breakdown of Value Sales for Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others for the Years 2020, 2026 & 2032
- Table 32: Canada Recent Past, Current & Future Analysis for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 33: Canada Historic Review for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 34: Canada 13-Year Perspective for Ureteral Stents by Material - Percentage Breakdown of Value Sales for Metallic Ureteral Stents and Polymer Ureteral Stents for the Years 2020, 2026 & 2032
- Table 35: Canada Recent Past, Current & Future Analysis for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 36: Canada Historic Review for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 37: Canada 13-Year Perspective for Ureteral Stents by Application - Percentage Breakdown of Value Sales for Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others for the Years 2020, 2026 & 2032
- Ureteral Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
- Table 38: Japan Recent Past, Current & Future Analysis for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 39: Japan Historic Review for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 40: Japan 13-Year Perspective for Ureteral Stents by Material - Percentage Breakdown of Value Sales for Metallic Ureteral Stents and Polymer Ureteral Stents for the Years 2020, 2026 & 2032
- Table 41: Japan Recent Past, Current & Future Analysis for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 42: Japan Historic Review for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 43: Japan 13-Year Perspective for Ureteral Stents by Application - Percentage Breakdown of Value Sales for Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others for the Years 2020, 2026 & 2032
- Ureteral Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
- Table 44: China Recent Past, Current & Future Analysis for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 45: China Historic Review for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 46: China 13-Year Perspective for Ureteral Stents by Material - Percentage Breakdown of Value Sales for Metallic Ureteral Stents and Polymer Ureteral Stents for the Years 2020, 2026 & 2032
- Table 47: China Recent Past, Current & Future Analysis for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 48: China Historic Review for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 49: China 13-Year Perspective for Ureteral Stents by Application - Percentage Breakdown of Value Sales for Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others for the Years 2020, 2026 & 2032
- Ureteral Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
- Table 50: Europe Recent Past, Current & Future Analysis for Ureteral Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- Table 51: Europe Historic Review for Ureteral Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 52: Europe 13-Year Perspective for Ureteral Stents by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
- Table 53: Europe Recent Past, Current & Future Analysis for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 54: Europe Historic Review for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 55: Europe 13-Year Perspective for Ureteral Stents by Material - Percentage Breakdown of Value Sales for Metallic Ureteral Stents and Polymer Ureteral Stents for the Years 2020, 2026 & 2032
- Table 56: Europe Recent Past, Current & Future Analysis for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 57: Europe Historic Review for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 58: Europe 13-Year Perspective for Ureteral Stents by Application - Percentage Breakdown of Value Sales for Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others for the Years 2020, 2026 & 2032
- Ureteral Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
- Table 59: France Recent Past, Current & Future Analysis for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 60: France Historic Review for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 61: France 13-Year Perspective for Ureteral Stents by Material - Percentage Breakdown of Value Sales for Metallic Ureteral Stents and Polymer Ureteral Stents for the Years 2020, 2026 & 2032
- Table 62: France Recent Past, Current & Future Analysis for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 63: France Historic Review for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 64: France 13-Year Perspective for Ureteral Stents by Application - Percentage Breakdown of Value Sales for Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others for the Years 2020, 2026 & 2032
- Ureteral Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
- Table 65: Germany Recent Past, Current & Future Analysis for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 66: Germany Historic Review for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 67: Germany 13-Year Perspective for Ureteral Stents by Material - Percentage Breakdown of Value Sales for Metallic Ureteral Stents and Polymer Ureteral Stents for the Years 2020, 2026 & 2032
- Table 68: Germany Recent Past, Current & Future Analysis for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 69: Germany Historic Review for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 70: Germany 13-Year Perspective for Ureteral Stents by Application - Percentage Breakdown of Value Sales for Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others for the Years 2020, 2026 & 2032
- Table 71: Italy Recent Past, Current & Future Analysis for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 72: Italy Historic Review for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 73: Italy 13-Year Perspective for Ureteral Stents by Material - Percentage Breakdown of Value Sales for Metallic Ureteral Stents and Polymer Ureteral Stents for the Years 2020, 2026 & 2032
- Table 74: Italy Recent Past, Current & Future Analysis for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 75: Italy Historic Review for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 76: Italy 13-Year Perspective for Ureteral Stents by Application - Percentage Breakdown of Value Sales for Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others for the Years 2020, 2026 & 2032
- Ureteral Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
- Table 77: UK Recent Past, Current & Future Analysis for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 78: UK Historic Review for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 79: UK 13-Year Perspective for Ureteral Stents by Material - Percentage Breakdown of Value Sales for Metallic Ureteral Stents and Polymer Ureteral Stents for the Years 2020, 2026 & 2032
- Table 80: UK Recent Past, Current & Future Analysis for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 81: UK Historic Review for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 82: UK 13-Year Perspective for Ureteral Stents by Application - Percentage Breakdown of Value Sales for Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others for the Years 2020, 2026 & 2032
- Table 83: Spain Recent Past, Current & Future Analysis for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 84: Spain Historic Review for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 85: Spain 13-Year Perspective for Ureteral Stents by Material - Percentage Breakdown of Value Sales for Metallic Ureteral Stents and Polymer Ureteral Stents for the Years 2020, 2026 & 2032
- Table 86: Spain Recent Past, Current & Future Analysis for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 87: Spain Historic Review for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 88: Spain 13-Year Perspective for Ureteral Stents by Application - Percentage Breakdown of Value Sales for Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others for the Years 2020, 2026 & 2032
- Table 89: Russia Recent Past, Current & Future Analysis for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 90: Russia Historic Review for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 91: Russia 13-Year Perspective for Ureteral Stents by Material - Percentage Breakdown of Value Sales for Metallic Ureteral Stents and Polymer Ureteral Stents for the Years 2020, 2026 & 2032
- Table 92: Russia Recent Past, Current & Future Analysis for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 93: Russia Historic Review for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 94: Russia 13-Year Perspective for Ureteral Stents by Application - Percentage Breakdown of Value Sales for Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others for the Years 2020, 2026 & 2032
- Table 95: Rest of Europe Recent Past, Current & Future Analysis for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 96: Rest of Europe Historic Review for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 97: Rest of Europe 13-Year Perspective for Ureteral Stents by Material - Percentage Breakdown of Value Sales for Metallic Ureteral Stents and Polymer Ureteral Stents for the Years 2020, 2026 & 2032
- Table 98: Rest of Europe Recent Past, Current & Future Analysis for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 99: Rest of Europe Historic Review for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 100: Rest of Europe 13-Year Perspective for Ureteral Stents by Application - Percentage Breakdown of Value Sales for Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others for the Years 2020, 2026 & 2032
- Ureteral Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
- Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Ureteral Stents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- Table 102: Asia-Pacific Historic Review for Ureteral Stents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 103: Asia-Pacific 13-Year Perspective for Ureteral Stents by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
- Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 105: Asia-Pacific Historic Review for Ureteral Stents by Material - Metallic Ureteral Stents and Polymer Ureteral Stents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 106: Asia-Pacific 13-Year Perspective for Ureteral Stents by Material - Percentage Breakdown of Value Sales for Metallic Ureteral Stents and Polymer Ureteral Stents for the Years 2020, 2026 & 2032
- Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- Table 108: Asia-Pacific Historic Review for Ureteral Stents by Application - Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- Table 109: Asia-Pacific 13-Year Perspective for Ureteral Stents by Application - Percentage Breakdown of Value Sales for Kidney Stones, Kidney Transplantation, Tumors, Urinary Incontinence and Others for the Years 2020, 2026 & 2032
- Ureteral Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
- Ureteral Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
REST OF ASIA-PACIFIC
LATIN AMERICA
- Ureteral Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
- Ureteral Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA
- Ureteral Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acer Therapeutics Inc.
- Aeglea BioTherapeutics Inc.
- Arcturus Therapeutics Holdings Inc.
- Abbott Laboratories Inc.
- Bausch Health Companies Inc.
- BioMarin Pharmaceutical Inc.
- Censa Pharmaceuticals Inc.
- Danone S.A.
- Eurocept Pharmaceuticals (Lucane Pharma SA)
- Horizon Therapeutics plc
- Mead Johnson & Company, LLC
- Moderna, Inc.
- Orpharma Pty Ltd.
- Precision BioSciences
- Recordati Rare Diseases Inc.
- Relief Therapeutics Holding AG
- Selecta Biosciences Inc.
- Swedish Orphan Biovitrum AB (Sobi)
- Synlogic Inc.
- Ultragenyx Pharmaceutical Inc.
- Xenion Biotech, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 381 |
| Published | November 2026 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value ( USD | $ 1.3 Billion |
| Forecasted Market Value ( USD | $ 1.6 Billion |
| Compound Annual Growth Rate | 3.0% |
| Regions Covered | Global |
